Welcome to our dedicated page for Biolinerx SEC filings (Ticker: BLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLineRx Ltd. (BLRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on NASDAQ and the Tel Aviv Stock Exchange. BioLineRx files annual reports on Form 20‑F and frequent current reports on Form 6‑K, which together document its financial performance, clinical progress and material corporate events.
Recent Form 6‑K filings referenced by the company include quarterly financial results for periods ended March 31, June 30 and September 30, 2025. These reports incorporate condensed consolidated interim financial statements and operating and financial reviews, giving detail on revenues from APHEXDA royalties, research and development expenses, general and administrative costs, and the company’s cash position and runway guidance.
Filings also cover transactional and strategic developments. For example, a September 29, 2025 Form 6‑K describes the joint venture agreement with Hemispherian AS and the asset transfer of GLIX1‑related intellectual property into a newly created company. The filing outlines ownership percentages, funding commitments, governance arrangements and rights related to additional assets in Hemispherian’s pipeline.
Other 6‑K submissions attach press releases on topics such as the USPTO Notice of Allowance for GLIX1 patents, as well as shareholder meeting results, including approvals of director elections, changes to authorized share capital, compensation policy updates and auditor appointments.
On Stock Titan, these BLRX filings are supplemented by AI‑powered summaries that explain the key points of each document in plain language. Users can quickly understand the implications of lengthy 20‑F and 6‑K reports, track changes in financial metrics over time, and identify disclosures related to clinical trials, licensing agreements, equity issuances and corporate governance. The page also links to information on insider and major shareholder activity when reported on applicable SEC forms.
BioLineRx Ltd. reported audited 2025 results and highlighted progress in its oncology and rare disease pipeline. Total revenues fell to $1,180 thousand in 2025 from $28,940 thousand in 2024, reflecting a sharp decline in license and product revenues. The loss attributable to owners narrowed to $1,175 thousand, versus $9,221 thousand in 2024, as operating loss decreased and non‑operating income supported results.
At December 31, 2025, cash and cash equivalents were $3,250 thousand and short-term deposits were $17,626 thousand, with total assets of $40,905 thousand and total equity of $23,345 thousand. Management expects to initiate a Phase 1/2a clinical trial of GLIX1 in glioblastoma by the end of March 2026 and continues a Phase 2b motixafortide trial in metastatic pancreatic cancer, alongside commercialization of APHEXDA for stem cell mobilization in multiple myeloma.
BioLineRx, an Israeli biopharma focused on oncology and rare diseases, highlights a high-risk financial profile despite having its first approved drug, APHEXDA (motixafortide), on the market via partners. The company recorded net losses of $60.6 million in 2023, $9.2 million in 2024 and $2.0 million in 2025, with an accumulated deficit of $401 million as of December 31, 2025.
Cash, cash equivalents and short-term deposits totaled $20.9 million at year-end 2025, which management believes will fund operations into the first half of 2027, yet auditors included a going-concern warning. BioLineRx has a secured loan with BlackRock, having drawn $30 million and later amending terms in November 2024 to repay remaining principal and interest through December 1, 2027, with a minimum cash covenant of $4 million and 10% of future out‑licensing milestones applied to debt reduction.
Strategically, BioLineRx out‑licensed motixafortide rights in Asia in October 2023 and globally ex‑Asia (excluding solid tumors) in November 2024, shut down independent U.S. commercialization, and refocused on development. In September 2025 it entered a collaboration with Hemispherian for GLIX1 in glioblastoma and other cancers, while implementing a one‑for‑forty effective reverse ADS split via an ADS ratio change in January 2025.
BioLineRx Ltd. chief financial officer Zeevi Mali filed an initial ownership report listing his equity position in the company. The filing shows multiple employee stock option grants over several years under the 2003 Amended and Restated Share Incentive Plan, alongside direct holdings of 1,311,000 Ordinary Shares.
The disclosed options cover underlying Ordinary Shares at exercise prices ranging from $0.0060 to $0.2870, with expiration dates between 2026 and 2035. Earlier grants from 2016 through 2022 are fully vested, while a grant dated March 21, 2023 is partly vested and continues to vest quarterly, and a large grant dated November 19, 2025 had no vested options initially and will vest over a one-year cliff and then 12 quarterly installments, subject to continued service. Certain securities tied to the plan are required to be registered in the name of a trustee to qualify for Israeli tax benefits.
BioLineRx Ltd. director Barbara-Jean Anne Bormann-Kennedy filed an initial Form 3 reporting her employee stock option holdings. She lists multiple options to buy Ordinary Shares granted under the 2003 Amended and Restated Share Incentive Plan, with exercise prices such as $0.8370, $0.3560, and $0.0520 per share and expirations between 2026 and 2034. One grant for 2,055,000 underlying shares at an exercise price of $0.0520 per share expires on August 14, 2034; footnotes state that 856,200 of these options were vested as of October 1, 2024, with the remaining 1,198,800 vesting in seven equal quarterly installments, subject to her continued service.
BioLineRx Ltd. filed a Form 6-K as a foreign private issuer reporting that it released its financial results for the three and nine months ended September 30, 2025. The company is furnishing a press release, unaudited condensed consolidated interim financial statements, and an operating and financial review for this period. These materials, including the section titled “Financial Results for the Quarter Ended September 30, 2025,” are incorporated by reference into all of its effective registration statements under the Securities Act of 1933.
BioLineRx Ltd. filed a Form 6-K to report that it has issued a press release announcing a USPTO Notice of Allowance for a key patent covering its GLIX1 candidate for treating a broad range of cancer types. This step means the U.S. patent office has indicated it intends to grant the patent, strengthening BioLineRx’s intellectual property position around GLIX1 and its potential oncology uses.
BioLineRx Ltd. has entered into a new joint venture with Norwegian company Hemispherian AS to develop, test, and commercialize GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma and other solid tumors. A new company has been formed, initially owned 60% by Hemispherian and 40% by BioLineRx.
Hemispherian transferred GLIX1-related intellectual property, regulatory filings, know-how, and associated assets to the joint venture. In return, BioLineRx committed to invest $5 million over up to 42 months under a staged development plan, with the risk that any unfunded portion could lead to a proportional repurchase of its stake for nominal consideration. BioLineRx can later increase its ownership up to 70% through additional investments, while Hemispherian may co-invest to maintain 50% once BioLineRx reaches that level.
BioLineRx will manage the joint venture’s operations and budget, while the joint venture will pay Hemispherian a monthly advisory fee of $80,000 for 24 months or until termination. Governance is shared through a board and steering committee where BioLineRx holds the deciding vote in deadlocks, and the joint venture receives first look and first refusal rights on other Hemispherian pipeline assets.
Highbridge Capital Management disclosed a 7.2% position in BioLineRx Ltd. represented by 172,950,600 Ordinary Shares assuming exercise of warrants held by Highbridge Funds. The filing states these shares are represented by 288,251 ADSs issuable upon exercise of warrants and that each ADS represents 600 Ordinary Shares. Highbridge reports sole voting and dispositive power over the 172,950,600 Ordinary Shares. The percentage is calculated using an outstanding share base of 2,232,601,990 Ordinary Shares as reported by the issuer.
BioLineRx Ltd. filed a Form 6-K as a foreign private issuer for August 2025, reporting that it has released its financial results for the three and six months ended June 30, 2025. The submission includes a press release, unaudited condensed consolidated interim financial statements, and an operating and financial review for that period. These materials are incorporated by reference into all of the company’s effective registration statements under the Securities Act of 1933, meaning those registration statements now formally include the newly reported interim financial information.